We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Lactotripeptides (Val-Pro-Pro / Ile-Pro-Pro)
Two milk-casein-derived tripeptides — Val-Pro-Pro (VPP) and Ile-Pro-Pro (IPP) — produced by fermenting milk with Lactobacillus helveticus or hydrolysing casein. They inhibit ACE in vitro and have been studied extensively for blood pressure. Honest appraisal: multiple meta-analyses find a small, statistically-significant drop in systolic/diastolic BP, but the effect is modest, heterogeneous, larger in Japanese than Western trials, and dented by clear publication bias plus outright-null trials (e.g. the Dutch Engberink RCT).
What the evidence says
Most Lactotripeptides studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality meta-analyses and randomised trials published 2004–2026.
Based on 35 studies · 7 meta-analyses · 25 RCTs
Confidence
High confidenceBy outcome
Seven meta-analyses find a small, statistically-significant blood-pressure drop, but the effect is modest, heterogeneous, larger in Japanese than Western trials, dented by publication bias, and contradicted by null RCTs like the Dutch Engberink trial.
31 rigorous studies
25 randomized trials · 6 meta-analyses · 1 systematic reviews
Our evidence rating for Lactotripeptides is accountable to this entire body of rigorous research indexed in PubMed — not a hand-picked subset.
PubMed · as of Jul 2026
Lactotripeptides are the casein-derived tripeptides isoleucine-proline-proline (IPP) and valine-proline-proline (VPP), generated when milk is fermented with Lactobacillus helveticus or casein is hydrolysed with Aspergillus oryzae protease.
Both peptides inhibit angiotensin-converting enzyme (ACE) in vitro, the same target as ACE-inhibitor blood-pressure drugs, and they survive gastrointestinal digestion well enough to reach the circulation intact (in vitro and pig pharmacokinetic data confirm absorption, albeit at a low fractional dose).
This is a food-derived, well-tolerated dietary peptide found in fermented-milk products — not a research compound.
The honest evidence picture is 'small but real, with real caveats.' At least seven meta-analyses of randomized placebo-controlled trials report statistically-significant reductions in systolic blood pressure (pooled effects roughly -1.3 to -5 mmHg) and smaller diastolic reductions.
But the effect is consistently larger in Japanese/Asian studies than in European ones (e.g.
Cicero 2011: SBP -6.9 mmHg in Asians vs a non-significant -1.2 mmHg in Caucasians), benefit concentrates in (pre)hypertensive rather than normotensive people, and several analyses (Fekete 2015, Pripp 2008) explicitly flag publication bias and 'small-study effects' that shift the true effect toward less impressive numbers.
A well-conducted Dutch RCT (Engberink 2008) found no effect on office, home, or 24-h ambulatory BP and no in-vivo ACE inhibition.
Net: lactotripeptides may offer a modest, drug-adjunct, lifestyle-modification-style BP benefit — most plausibly in mildly hypertensive individuals — but they are far weaker than antihypertensive medication and should not be presented as a replacement for it.
VPP and IPP competitively inhibit angiotensin-converting enzyme (ACE1) in vitro — the same renin-angiotensin-system target as ACE-inhibitor drugs — reducing formation of the vasoconstrictor angiotensin II. The in-vivo relevance is debated: some trials saw no measurable plasma ACE inhibition.
Their proline-rich structure resists gastrointestinal peptidases, so a fraction of the intact tripeptides survives digestion and is absorbed (shown in Caco-2 monolayers and a pig pharmacokinetic model), allowing them to reach the circulation in active form.
Beyond ACE inhibition, some trials report improved central arterial compliance and arterial stiffness, consistent with an endothelial/vascular-tone effect — though this mechanism is less firmly established than the ACE-inhibition rationale.
How Lactotripeptides works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Avoid — these are casein-derived peptides.
Lactotripeptides occur naturally in fermented-milk foods and are likely safe as a dietary component; dedicated supplement-dose trials in pregnancy are lacking, so use normal dietary judgment and consult a clinician before using concentrated products.
Safe to combine in most cases, but monitor BP for additive lowering and do not substitute for prescribed therapy.
Theoretical additive blood-pressure-lowering effect via the same RAAS target; trials suggest concomitant antihypertensive medication does not blunt the (small) peptide effect, but monitor for additive hypotension if combining.
Tip: Discontinue if dairy-related GI symptoms occur
Tip: Choose a low-lactose preparation or a non-fermented hydrolysate/tablet form
Lactotripeptides has an evidence score of 4.5/10 — emerging evidence based on 25 indexed studies, including 7 meta-analyses. Two milk-casein-derived tripeptides — Val-Pro-Pro (VPP) and Ile-Pro-Pro (IPP) — produced by fermenting milk with Lactobacillus helveticus or hydrolysing casein. They inhibit ACE in vitro and have been studied extensively for blood pressure. Honest appraisal: multiple meta-analyses find a small, statistically-significant drop in systolic/diastolic BP, but the effect is modest, heterogeneous, larger in Japanese than Western trials, and dented by clear publication bias plus outright-null trials (e.g. the Dutch Engberink RCT). Representative study: PMID 25608938.
The commonly studied dose of Lactotripeptides is ~3-5 mg combined VPP + IPP per day (the dose used in most positive fermented-milk trials). Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Timing is flexible for Lactotripeptides — consistent daily use matters more than the time of day. Delivered in fermented-milk drinks, sour-milk products, or tablets; usually taken once daily with no strict time-of-day requirement.
Lactotripeptides is generally well-tolerated and considered safe for most healthy adults at recommended doses. Reported side effects are uncommon and include dairy-related GI upset (in lactose-intolerant individuals consuming milk-based products), generally well tolerated; side effects comparable to placebo in trials. Use caution if any of these apply to you: Milk / dairy allergy (these are milk-casein-derived peptides); Galactosemia (avoid milk-based products).
Casein Hydrolysate
Mostly mechanism / observationalA milk-derived bioactive peptide — a tryptic hydrolysate of bovine αs1-casein standardized to the decapeptide α-casozepine (Lactium) — marketed for stress, anxiety, and sleep. Honest appraisal: the mechanism is real and food-derived (α-casozepine binds the benzodiazepine site of the GABA-A receptor in vitro), and a handful of small human RCTs show modest reductions in stress symptoms and cortisol plus some sleep-diary improvements. But several trials are industry-linked, two well-designed sleep RCTs were null on their primary endpoint, and effects are small. Well-tolerated; this is an ordinary dietary supplement, not a drug.
Bonito Peptides
Mostly mechanism / observationalShort ACE-inhibitory peptides from enzyme-digested dried bonito (Katsuobushi) fish muscle — notably the dipeptide Val-Tyr ("VY") and the prodrug-type pentapeptide LKPNM — sold as a food-derived supplement for blood pressure. Honest appraisal: a handful of small, mostly Japanese, often industry-linked RCTs show a modest blood-pressure drop in people with mild/high-normal hypertension, on the same ACE-inhibition mechanism as related fish/sardine and milk (lactotripeptide) peptides. The effect is small, the trials are small, and benefit concentrates in (pre)hypertensive people — not normotensives.
Glycomacropeptide
Mostly mechanism / observationalA 64-amino-acid peptide released from kappa-casein during cheese-making, sold both as a whey-derived satiety supplement and (amino-acid-fortified) as a low-phenylalanine protein for PKU. Honest appraisal: the appetite/satiety evidence is genuinely mixed — several acute RCTs found NO effect of GMP itself on CCK, satiety ratings, or food intake, while a few found small reductions in energy intake. Its established, evidence-supported use is as a near-phenylalanine-free protein substitute in phenylketonuria, where it works as well as (not clearly better than) amino-acid formulas.
Soy Peptides
Mostly mechanism / observationalShort, bioactive fragments enzymatically cleaved from soy protein — soy protein hydrolysates plus named peptides like lunasin and soy ACE-inhibitory peptides. Unlike whole soy protein (a complete protein with an FDA cholesterol claim) or soy isoflavones (phytoestrogens), these are specific peptide fragments studied for cholesterol, blood pressure and antioxidant effects. Honest appraisal: the evidence is mostly in-vitro and animal. The one published human RCT (lunasin) was null. Emerging, not established.
Explore: Best supplements for Vitality & Longevity
Reviewed by Dr. Baher Al Hakim · Last reviewed June 2026 · evidence from 35 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tap node to isolate • Pinch to zoom • Tap edge for research